Patents Assigned to Merck
  • Synthetic virus like particles with heterologous epitopes
    Patent number: 6689366
    Abstract: The invention is a series of synthetic virus-like particles comprising a heterologous conformational epitope useful in the characterization of human papillomavirus infection, and useful to vaccinate individual for protection against HPV 6 and HPV 11 infections, and assays employing the synthetic virus-like particles.
    Type: Grant
    Filed: June 4, 2001
    Date of Patent: February 10, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Kathrin U. Jansen, Jessica C. Ling, Steven W. Ludmerer, William L. McClements, Xin-Min Wang
  • Nucleic acid encoding rat agouti related protein
    Patent number: 6689873
    Abstract: This invention concerns nucleic acid encoding for rat agouti related protein. Agouti related protein is a neuropeptide that may play a role in the central regulation of feeding behavior and energy metabolism via interactions with the melanocortin pathways. This invention also relates to assays utilizing the novel nucleic acid of this invention.
    Type: Grant
    Filed: April 27, 2001
    Date of Patent: February 10, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Leonardus H. T. Van der Ploeg, Xiaoming Guan, Hong Yu, Prashant G. Trivedi
  • High level expression of human cyclooxygenase-2
    Patent number: 6689596
    Abstract: The invention discloses a cDNA consisting of human cyclooxygenase-2 cDNA attached to 3′ flanking sequence of human cyclooxygenase-1 methods for increasing the expression of human cyclooxygenase-2 in transformed cells and assays for preferentially and independently measuring cyclogenase-2 in samples.
    Type: Grant
    Filed: October 25, 2001
    Date of Patent: February 10, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Gary P. O'Neill, Joseph A. Mancini
  • Method for producing thienopyrimidines
    Patent number: 6689885
    Abstract: The invention relates to a process for preparing compounds of the formula I In this process a 2-aminobenzothiophene-3-carboxylic ester of the formula II is reacted with a nitrile of the formula III N≡C—R1   III in solution or suspension in a solvent in the presence of an acid.
    Type: Grant
    Filed: October 21, 2002
    Date of Patent: February 10, 2004
    Assignee: Merck Patent GmbH
    Inventors: Horst Juraszyk, Peter Wendel, Markus Woissyk
  • Liquid-crystalline medium
    Patent number: 6689291
    Abstract: A liquid-crystalline medium based on a mixture of polar compound shaving positive dielectric anisotropy, characterized in that it contains one or more fluorophenylcyclohexene derivatives of the formula I in which R is H, an unsubstituted alkyl or alkenyl radical having up to 18 carbon atoms, in which one or more non-adjacent CH2 groups are optionally replaced by —O—, —S—, —CO—, —O—CO—, —CO—O— or —C≡C—, X is CN or Q—Y, Y is H, F or Cl, Q is —CF2—, —CHF—, —OCF2—, —OCHF—, —OCH2CF2—, —CH═CF—, —CF═CH—, —CF═CF—, —O—CF═CF—, —O—CH═CF— or a single bond, m is 0 or 1, and n is 0, 1 or 2.
    Type: Grant
    Filed: April 8, 1994
    Date of Patent: February 10, 2004
    Assignee: Merck Patent Gesellschaft mit Beschrankter Haftung
    Inventors: Volker Reiffenrath, Detlet Pauluth, Herbert Plach
  • Multilayer interference pigments
    Patent number: 6689205
    Abstract: Multilayer interference pigment consisting of a transparent carrier material coated with alternating layers of metal oxides of low and high refractive index, the difference in the refractive indices being at least 0.1, which is obtainable by alternate coating of the transparent carrier material with a metal oxide of high refractive index and with a metal oxide of low refractive index in a wet process by hydrolysis of the corresponding water-soluble metal compounds, separation, drying and, if desired, calcination of the resulting pigment.
    Type: Grant
    Filed: October 24, 2000
    Date of Patent: February 10, 2004
    Assignee: Merck Patent Gesellschaft
    Inventors: Hans-Dieter Brückner, Andrea Heyland, Christoph Schmidt, Christina Schank, Claudia Seibel
  • Liquid-crystalline medium
    Patent number: 6685996
    Abstract: The invention relates to a liquid-crystalline medium based on a mixture of polar compounds having positive dielectric anisotropy, characterized in that it comprises one or more compounds of the general formula I in which R, A1, Z1, Y and L are as defined in claim 1.
    Type: Grant
    Filed: July 2, 2001
    Date of Patent: February 3, 2004
    Assignee: Merck Patent GmbH
    Inventors: Kazuaki Tarumi, Brigitte Schuler, Eike Poetsch, Volker Reiffenrath, Yukiomi Tanaka
  • Conjugate, its preparation and use
    Patent number: 6685924
    Abstract: The invention relates to a conjugate which can be used for preparing dermatological and cosmetic compositions. The invention also relates to processes for preparing such conjugate and to its use.
    Type: Grant
    Filed: November 7, 2001
    Date of Patent: February 3, 2004
    Assignee: Merck Patent GmbH
    Inventors: Herwig Buchholz, Ralf Anselmann, Hansjuergen Driller, Michael Kirschbaum, Frank Pflücker
  • Solutions and processes for removal of sidewall residue after dry etching
    Publication number: 20040016719
    Abstract: The present invention relates to a novel process for removing sidewall residue after dry-etching process. Conventionally, after dry-etching, photoresist and sidewall residues are removed by ozone ashing and hot sulfuric acid. Normally, they are hard to be removed completely. It was found in the present invention that the addition of fluorine-containing compound, preferably hydrogen fluoride and ammonium fluoride, in sulfuric acid results in complete removal of photoresist and sidewall residue without the need for stripper. The process is simple and does not affect the original procedures or the other films on the substrate. The present invention also relates to a novel solution for removing sidewall residue after dry-etching, which comprises sulfuric acid and a fluorine-containing compound, preferably hydrogen fluoride and ammonium fluoride, in the range of from 10:1 to 1000:1 by weight.
    Type: Application
    Filed: July 17, 2003
    Publication date: January 29, 2004
    Applicant: Merck Patent GmbH
    Inventors: Ming-Chi Liaw, Tieng-Sheng Chao, Tan-Fu Lei
  • Human calcium channel compositions and methods
    Publication number: 20040018510
    Abstract: Isolated DNA encoding each of human calcium channel &agr;1-, &agr;2-, &bgr;- and &ggr;-subunits, including subunits that arise as splice variants of primary transcripts, is provided. Cells and vectors containing the DNA and methods for identifying compounds that modulate the activity of human calcium channels are also provided.
    Type: Application
    Filed: February 27, 2003
    Publication date: January 29, 2004
    Applicant: Merck & Co., Inc.
    Inventors: Michael M. Harpold, Steven B. Ellis, Mark E. Williams, Ann F. McCue, Alison Gillespie, Daniel H. Feldman, Robert Brenner
  • Liquid-crystalline medium
    Publication number: 20040016905
    Abstract: The invention relates to a liquid-crystalline medium based on a mixture of polar compounds of positive dielectric anisotropy, characterized in that it comprises one or more compounds of the formula I 1
    Type: Application
    Filed: May 27, 2003
    Publication date: January 29, 2004
    Applicant: Merck Patent GmbH
    Inventors: Michael Heckmeier, Brigitte Schuler, Izumi Saito, Volker Reiffenrath, Georg Luessem, Christian Hock
  • Recovery of isoquercetin from bioflavanoid pastes
    Patent number: 6683164
    Abstract: The invention relates to a method for recovering high-purity isoquerectin from bioflavonoid pastes, that is from mother-liquor residues which are produced during the recovery of flavonoids, by extraction with a solvent mixture of methyl acetate and water.
    Type: Grant
    Filed: May 10, 2002
    Date of Patent: January 27, 2004
    Assignee: Merck Patent GmbH
    Inventors: Herwig Buchholz, Michael Jungnitz, Michael Grund, Ralf Rosskopf, Hartmut Härtner
  • Pharmaceutical preparation containing a cyclopeptide and a chemotherapeutic agent or an angiogenesis inhibitor
    Patent number: 6683051
    Abstract: The invention relates to a pharmaceutical preparation [lacuna] cyclo(Arg-Gly-Asp-D-Phe-NMe-Val) and/or one of its physiologically acceptable salts and at least one chemotherapeutic agent and/or one of its physiologically acceptable salts and/or an angiogenesis inhibitor and/or one of its physiologically acceptable salts.
    Type: Grant
    Filed: June 4, 2001
    Date of Patent: January 27, 2004
    Assignee: Merck Patent GmbH
    Inventors: Alfred Jonczyk, Astrid Perschl, Simon Goodman, Sigrid Rösener, Jutta Haunschild
  • Electrooptical liquid crystal system
    Patent number: 6682661
    Abstract: To improve switching times, especially at low temperatures, one or more reactive liquid crystalline compounds is added to a liquid crystal mixture used in an electroptical system. The electroptical system comprises a PDLC film comprising a liquid crystal mixture forming micro-droplets in an optically isotropic, transparent polymer matrix between 2 electrode layers. The liquid crystal mixture comprises one or more compounds of the formula I wherein R, A1, A2, Z1, Z2, X1, X2, Q, Y and n are as defined herein.
    Type: Grant
    Filed: March 18, 2002
    Date of Patent: January 27, 2004
    Assignee: Merck Patent Gesellschaft
    Inventors: David Coates, Owain Llyr Parri, Simon Greenfield, Martin David Tillin, Mark John Goulding, Patrick Nolan
  • Mouse growth hormone secretagogue receptor
    Patent number: 6682908
    Abstract: A mouse growth hormone secretagogue receptor has been isolated, cloned and sequenced. This receptor is characteristic of the G-protein family of receptors. Mouse growth hormone secretagogue receptors may be used to screen and identify compoumds which bind to the mouse growth hormone secretagogue receptor. Such compounds may be used in the treatment of conditions which occur when there is a shortage of growth hormone, such as observed in growth hormone deficient children, elderly patients with musculoskeletal impairment and those recovering from hip fracture and osteoporosis. Targeted disruption of the mouse GHS-R gene may prove useful in elucidation of the mechanism of action and role of the growth hormone secretagogues in human and animal physiology.
    Type: Grant
    Filed: June 13, 2001
    Date of Patent: January 27, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Roy G. Smith, Leonardus H. T. Van der Ploeg, Andrew D. Howard, Hui Zheng, Karen Kulju McKee, Michael M. Jiang
  • Liquid-crystalline medium
    Publication number: 20040011996
    Abstract: The present invention relates to a liquid-crystalline medium based on a mixture of compounds of negative dielectric anisotropy comprising one or more polymerizable compounds, and to the use thereof for electro-optical purposes, and to displays containing this medium.
    Type: Application
    Filed: July 3, 2003
    Publication date: January 22, 2004
    Applicant: Merck Patent GmbH
    Inventors: Melanie Klasen-Memmer, Dagmar Klement, Matthias Bremer
  • Colored inscription and marking of plastics and surface coatings
    Publication number: 20040013969
    Abstract: The present invention relates to the colored inscription or marking of plastics and surface coatings, including powder coatings, in which a colorant is transferred into the plastic or surface coating by laser radiation with the aid of a laser light-absorbent substance.
    Type: Application
    Filed: July 26, 2002
    Publication date: January 22, 2004
    Applicant: Merck Patent GmbH
    Inventors: Reiner Delp, Matthias Kuntz
  • Body pigment and process for preparaing the same
    Publication number: 20040011253
    Abstract: A body pigment with a good skin feel for cosmetics is provided which has an appropriate crumbling property and combines slipping property and adhesiveness without compromising oil absorption. The body pigment is comprised of a metallic compound and has a structure in which leaf-shaped flakes are combined and/or intersected.
    Type: Application
    Filed: March 11, 2003
    Publication date: January 22, 2004
    Applicant: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventor: Tamio Noguchi
  • Anti-hypercholesterolemic drug combination
    Patent number: 6680340
    Abstract: This invention provides a drug combination comprised of a thyroid hormone receptor beta agonist with a fibrate in therapeutically effective amounts, which is useful for reducing cholesterol synthesis, lowering plasma cholesterol levels and lowering plasma triglyceride levels.
    Type: Grant
    Filed: February 13, 2003
    Date of Patent: January 20, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Kang Cheng, Samuel D. Wright, Tsuei-Ju Wu
  • Supply system for chemicals and its use
    Patent number: 6679764
    Abstract: The present invention relates to a novel supply system for chemicals which permits the preparation of solid-containing suspensions, which are required, inter alia, for polishing wafers or in semiconductor production, directly at the point of use.
    Type: Grant
    Filed: February 27, 2001
    Date of Patent: January 20, 2004
    Assignee: Merck Patent GmbH
    Inventors: Ulrich Finkenzeller, Claus Dusemund, Thomas Schwortschik